JNJ

237.69

+1.42%↑

UNH

268.72

-2.61%↓

TMO

542.22

-4.11%↓

ABT

109.21

+1.05%↑

ISRG

476.27

-0.36%↓

JNJ

237.69

+1.42%↑

UNH

268.72

-2.61%↓

TMO

542.22

-4.11%↓

ABT

109.21

+1.05%↑

ISRG

476.27

-0.36%↓

JNJ

237.69

+1.42%↑

UNH

268.72

-2.61%↓

TMO

542.22

-4.11%↓

ABT

109.21

+1.05%↑

ISRG

476.27

-0.36%↓

JNJ

237.69

+1.42%↑

UNH

268.72

-2.61%↓

TMO

542.22

-4.11%↓

ABT

109.21

+1.05%↑

ISRG

476.27

-0.36%↓

JNJ

237.69

+1.42%↑

UNH

268.72

-2.61%↓

TMO

542.22

-4.11%↓

ABT

109.21

+1.05%↑

ISRG

476.27

-0.36%↓

Home・Aandelen Lijst・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Open

SectorGezondheidszorg

462.29 -3.77

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

456.89

Max

484.09

Belangrijke statistieken
By Trading Economics
Inkomsten	-72M -114M
Verkoop	74M 287M
Winstmarge	-39.75
Werknemers	528
EBITDA	-68M -106M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+46.25% upside

Dividenden
By Dow Jones
Volgende Winsten	19 feb 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	1.9B 11B
Vorige openingsprijs	466.06
Vorige sluitingsprijs	462.29

Nieuwssentiment

By Acuity

45%

55%

133 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

263.2 / 277.1 Steun & Weerstand

Madrigal Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 feb 2026, 00:00 UTC

Populaire aandelen

Stocks to Watch: Crown Castle, Qualcomm, Arm, U-Haul

4 feb 2026, 22:55 UTC

Winsten

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook -- Update

4 feb 2026, 21:44 UTC

Winsten

Arm Holdings 3Q Profit Falls Despite Revenue Growth

4 feb 2026, 21:39 UTC

Winsten

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook

5 feb 2026, 00:00 UTC

Winsten

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

5 feb 2026, 00:00 UTC

Winsten

Renesas Electronics FY Loss Y51.76B Vs Net Y219.08B

4 feb 2026, 23:46 UTC

Marktinformatie

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

4 feb 2026, 23:45 UTC

Winsten

Google to Double Spending as Earnings Beat Wall Street Expectations -- 4th Update

4 feb 2026, 23:32 UTC

Marktinformatie

Gold Rises on Possible Dip-Buying Amid Lingering U.S.-Iran Tensions -- Market Talk

4 feb 2026, 22:59 UTC

Acquisities, Fusies, Overnames

SiTime to Buy Timing Business From Renesas Electronics For $1.5B

4 feb 2026, 22:30 UTC

Winsten

Salesforce Stock Is Battered, and Super Cheap. Hang Tight. -- Barrons.com

4 feb 2026, 22:30 UTC

Winsten

Alphabet's Cloud Is Shining as CapEx Heads Even Higher -- Barrons.com

4 feb 2026, 22:21 UTC

Winsten

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4 feb 2026, 22:17 UTC

Marktinformatie

WiseTech Faces Risks in Both Directions From DSV's Progress -- Market Talk

4 feb 2026, 22:15 UTC

Marktinformatie

Santos Should Lay Out Strategic Plans at Annual Result -- Market Talk

4 feb 2026, 22:00 UTC

Marktinformatie

ESG Roundup: Market Talk

4 feb 2026, 21:53 UTC

Winsten

Google to Double Spending as Earnings Beat Wall Street Expectations -- 3rd Update

4 feb 2026, 21:51 UTC

Winsten

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

4 feb 2026, 21:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

4 feb 2026, 21:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

4 feb 2026, 21:50 UTC

Marktinformatie

Winsten

Auto & Transport Roundup: Market Talk

4 feb 2026, 21:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

4 feb 2026, 21:45 UTC

Winsten

Arm Holdings Reported Record Revenue. The Stock is Falling. -- Barrons.com

4 feb 2026, 21:44 UTC

Winsten

Qualcomm Gives Weak Guidance. The CEO Blames Memory Crunch. -- Barrons.com

4 feb 2026, 21:43 UTC

Winsten

Google to Double Spending as Earnings Beat Wall Street Expectations -- 2nd Update

4 feb 2026, 21:41 UTC

Winsten

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4 feb 2026, 21:36 UTC

Marktinformatie

Latest Canada Green Bond Raises C$2 Billion -- Market Talk

4 feb 2026, 21:30 UTC

Winsten

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4 feb 2026, 21:30 UTC

Winsten

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

4 feb 2026, 21:30 UTC

Winsten

Beach Energy Interim Dividend 1 Australian Cent/Sjare

Peer Vergelijking

Prijswijziging

Madrigal Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

46.25% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 705.56 USD 46.25%

Hoogste 964 USD

Laagste 570 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Madrigal Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan Madrigal Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

263.2 / 277.1Steun & Weerstand

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

133 / 352 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.